Reduction of Atrial Fibrillation Study in Patients Undergoing Coronary Artery Bypass Grafting. (RASCABG 1 Study)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00287209|
Recruitment Status : Completed
First Posted : February 6, 2006
Last Update Posted : February 6, 2006
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation Coronary Artery Bypass Grafting||Drug: Amiodarone||Phase 4|
New-onset atrial fibrillation (AF) after coronary bypass grafting (CABG) is common, with an incidence ranging from 5%-65%.
Although postoperative atrial tachyarrhythmia is often regarded as a temporary problem related to the operation and therefore innocuous, this complication has clinically significant adverse effects on patient outcome.
The purpose of this study was to find a good treatment without severe adverse effects to minimize the incidence of AF and maybe reduced the hemodynamic stress which AF is well known to cause. This would indicate that the risk of developing fatal events like cerebral apoplexy, TCI, AMI and death will be minimized as a result of the improved hemodynamic.
Overall AF is associated with risk of illness and for the development of severe complications as cerebral apoplexy, TCI, AMI and death with a factor 2-3.
There has furthermore been seen a twofold increase in the duration of intensive care unit stay and prolongation of the total hospitalization time with attendant increased hospitalization cost.
The outbreak of AF after CABG has been increasing over the last twenty years. It is speculated that the reason for this rise in incidence is due to the advancing age in the patient populations, more complex cardiac surgery as due to former underestimation of the arrhythmia.
Medical therapy includes various drugs, such as β-blockers, calcium channel blockers, digoxin, sotalol, quinidine, and amiodarone among others, to control heart rate and restore sinus rhythm. Most of these antiarrhythmic agents have significant cardiac and noncardiac adverse effects , why the use of these drugs should be minimized to a short period of time. Amiodarone is well known drug to treat AF and diminish the incidence of AF after CABG operation. So far there has not been any study focusing on postoperative high doses treatment with oral administrated amiodarone. The studies which have been publicized are studies where the drug was administrated intravenously pre-, post- or both pre- and postoperative. Some studies have orally administrated the drug in different regimes11 but no study has yet shown the possible affect of solitarily postoperative administrated high doses amiodarone after an intravenously administrated bolus, with the affect of getting loaded immediately.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||250 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Reduction of Atrial Fibrillation Study in Patients Undergoing Coronary Artery Bypass Grafting. (RASCABG 1 Study)|
|Study Start Date :||January 2004|
|Estimated Study Completion Date :||August 2005|
- - Time to symptomatic atrial fibrillation, cerebral apoplexy/ transitory cerebral infarction (TCI), acute myocardial infarction (AMI), or death.
- - Time to symptomatic or asymptomatic atrial fibrillation, cerebral apoplexy/TCI, AMI or death;
- - Time to symptomatic or asymptomatic atrial fibrillation
- - Time to symptomatic atrial fibrillation
- All measured at postoperative day 7 and 30.
- - Length of stay at Skejby Sygehus.
- - Length of stay at Skejby Sygehus and local hospital.
- - Length of stay at the intensive care unit (ICU) and intermediary unit, Skejby Sygehus
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00287209
|Department of Cardiothoracic and Vascular Surgery & Institute of Clinical Medicine, Skejby Sygehus, Aarhus University Hospital|
|Aarhus N, Denmark, 8200|
|Principal Investigator:||Vibeke E Hjortdal, Professor||Department of Cardiothoracic and Vascular Surgery & Institute of Clinical Medicine, Skejby Sygehus, Aarhus University Hospital, DK-8200 Aarhus N, Denmark|